In midday trading, Intel rose approximately 1.2% despite a 60% drop in 2024, potentially marking its worst year. Nvidia fell 1.3% as it attracted profit-taking, yet is still up over 170% for the year, making it a top S&P 500 performer. Sangamo Therapeutics plummeted 54% after Pfizer ended a partnership for a hemophilia gene therapy, while Biohaven gained nearly 2% after a director’s significant share purchase. Nutriband shares surged over 8% amid expectations for expedited approval of its opioid patch, and Zivo Bioscience rose nearly 3% following a large purchase by an investor.
